NEW BRUNSWICK, N.J.,
May 18, 2016 /PRNewswire/ -- At
a meeting today with the investment community, senior leaders from
the Johnson & Johnson Family of Companies (NYSE: JNJ) will
review strategies and opportunities for growth in the Consumer and
Medical Device segments. The company will highlight the strategic
advantages of its broad base in human health care, its holistic
approach to innovation and its strategy to achieve above-market
growth across the enterprise.
"The way we are approaching innovation goes beyond products and
services," said Alex Gorsky,
Chairman and CEO of Johnson & Johnson. "We are innovating how
we go to market, how we reach new consumers, and how we use
technology to drive better outcomes and deliver long-term value to
patients, consumers and customers around the world."
Today's meeting will also feature new insight into the company's
increased focus on leading in the Health-Tech space – the
intersection between health care and technology. Johnson &
Johnson is creating new engagement models, building a more flexible
and secure digital business, and developing smarter products.
"We have the right internal capabilities, and are developing
strategic partnerships in health care technology, to reshape the
way health care is delivered, managed and experienced," said
Gorsky.
Medical Devices
Johnson & Johnson has the world's most comprehensive Medical
Devices business, with $25.1 billion
in total sales for 2015, driven by 11 $1
billion-plus platforms. Johnson & Johnson competes in
the estimated $370 billion global
Medical Devices market, including hospital medical devices in the
Surgery, Orthopaedics and Cardiovascular and Specialty Surgery
categories, and in the consumer-facing medical device categories of
Vision Care and Diabetes Care.
In its hospital medical device businesses, the company holds
global leadership positions in Surgery and Orthopaedics, as well as
key regional leadership positions in China and other emerging markets. With plans
to file more than 20 major new products through 2018, expanding its
global presence and implementing novel commercial models, the
company expects to deliver above-market growth within the next
year. The business is also continuing to accelerate its pace of
innovation, and estimates its current pipeline of products –
expected to be filed for regulatory approval by 2018 – has greater
than $6 billion in sales
potential.
The company's consumer medical device businesses have leading
positions and are poised for growth. Johnson & Johnson
Vision Care, the global market leader in contact lenses, expects to
grow market share and exceed the industry pace of innovation by
delivering two new products per year through 2020. The Johnson
& Johnson Diabetes Care Companies, market leading in blood
glucose monitoring, are increasing their competitiveness and expect
improved market penetration globally to reach more patients.
Combined, these businesses have a robust innovation agenda with a
current pipeline of products expected to be filed for regulatory
approval by 2018, with sales potential greater than $2 billion.
Consumer
The Johnson & Johnson Consumer business competes in
categories that total $350 billion
globally, and those categories are growing at a weighted average of
more than 4 percent. The business has three $1 billion brands today, and expects to expand
that to five $1 billion brands by
2020.
The Consumer segment is well positioned to grow sales above the
market, while continuing to expand margins to achieve benchmark
levels of profitability. With its focus on science-based,
professionally endorsed products, the Consumer business expects to
accelerate growth with a differentiated innovation pipeline,
including more than 100 new products this year.
About Today's Meeting
The meeting will be webcast starting at 9
a.m. EDT today and can be accessed along with full copies of
the presentations and speaker biographies via the Johnson &
Johnson Investor Relations website: www.investor.jnj.com. A replay
and podcast will be available approximately two hours after the
live webcast. A live Twitter feed for today's meeting is accessible
via #JNJ16BR.
Users of the Johnson & Johnson Investor Relations mobile app
for the iPad® and iPhone® mobile digital devices can also access
the event. This free app is available in the iTunes® store and
includes stock information, news releases, company information,
webcasts, SEC filings, and the company's pharmaceutical product
pipeline, among other information.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites
the people of Johnson & Johnson. We embrace research and
science – bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
127,500 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
This release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995 regarding,
among other things, future operating and financial performance,
product development, market position and business strategy. The
reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson
& Johnson. Risks and uncertainties include, but are not limited
to: challenges and uncertainties inherent in new product
development, including uncertainty of clinical success and
decisions of regulatory authorities regarding approval, labeling
and other matters that could affect the availability or commercial
potential of product candidates; uncertainty of commercial success
for new and existing products; the ability of the company to
successfully execute strategic plans, including restructuring
plans; competition, including technological advances, new products
and patents attained by competitors; impact of business
combinations and divestitures; challenges to patents; changes to
applicable laws and regulations, including global health care
reforms; trends toward health care cost containment; changes in
behavior and spending patterns or financial distress of purchasers
of health care products and services; product efficacy or safety
concerns resulting in product recalls or regulatory action;
manufacturing difficulties or delays; significant adverse
litigation or government action, including related to product
liability claims; financial instability of international economies
and legal systems; and increased scrutiny of the health care
industry by government agencies. A further list and
description of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended January 3, 2016,
including in Exhibit 99 thereto, and the company's subsequent
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov,
www.investor.jnj.com, or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of
the date of this release. Johnson & Johnson does not undertake
to update any forward-looking statement as a result of new
information or future events or developments.
iPad, iPhone and iTunes are trademarks of Apple Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-showcasing-its-broad-innovation-and-technology-strategies-in-consumer-and-medical-device-businesses-300270532.html
SOURCE Johnson & Johnson